Enzyvant

Enzyvant to build regenerative medicine manufacturing plant in North Carolina
Fierce Pharma
Thu, 04/21/22 - 10:42 am
Enzyvant
North Carolina
regenerative medicine
drug manufacturing
An FDA mistake signals likely approval for Vivek Ramaswamy’s first therapy for children born without a thymus
Endpoints
Fri, 10/1/21 - 10:50 am
Enzyvant
Vivek Ramaswamy
FDA
congenital athymia
Already on Fast Track, Aceragen Launches with $35 Million and Farber Disease Drug
BioSpace
Mon, 05/3/21 - 10:52 pm
Aceragen
Farber Disease
RVT-801
Enzyvant
FDA knocks down Enzyvant candidate on manufacturing concerns after plant inspection
Fierce Biotech
Fri, 12/6/19 - 09:59 am
Enzyvant
FDA
drug manufacturing
congenital athymia
RVT-802